Previous 10 | Next 10 |
Citi has upgraded Arcturus Therapeutics to buy from neutral saying that the company's recent strategic collaboration with CSL Sequirus validates its mRNA platform. The firm has a $35 price target (~61% upside based on Wednesday's close). Analyst Yigal Nochomovitz noted tha...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ricochet64 / Shutterstock.com Rogers Corporation (NYSE: ROG ) stock is falling hard on Wednesday following confirmation that DuPont (NYSE: DD ) no longer plans to acquire the company. Several sou...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock.com Benefitfocus (NASDAQ: BNFT ) stock is rocketing higher on Wednesday as investors react to a $570 million acquisition deal with Voya Financial (NYSE: VOYA ). That deal will see ...
Shares of Arcturus Therapeutics Holdings (NASDAQ: ARCT) are skyrocketing today, up by 26.5% as of 11:15 a.m. ET. The huge gain came after Arcturus announced yesterday that it has entered into a strategic collaboration with CSL Seqirus, a unit of CSL Limited (OTC: CSLL.Y) . T...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips A strategic collaboration has today’s traders talking about Arcturus Therapeutics (NASDAQ: ARCT ) and CSL (OTCMKTS: CSLLY ). Reportedly, the two companies will work together on mRNA technology for a w...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eric Urquhart/Shutterstock.com It’s time to take a look at all of the latest news behind the biggest pre-market stock movers on Thursday! Moving stocks this morning are acquisitions, collaborations, a...
Arcturus Therapeutics ( NASDAQ: ARCT ) surges 32,4% after-hours on Tuesday after the firm enters a strategic collaboration with CSL Seqirus to provide former with a license to their self-amplifying mRNA technology to support the research, development, manufacture, and...
Arcturus to receive upfront payment of $200 million and more than $4 billion in potential development and commercial milestones 40% profit sharing for COVID-19 vaccines, up to double digit royalties for influenza, pandemic preparedness and three additional respiratory infect...
CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology PR Newswire KING OF PRUSSIA, Pa. , Nov. 1, 2022 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has ...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory r...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...